treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.

Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.